Edition:
India

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.25EUR
19 Jan 2018
Change (% chg)

€-0.02 (-0.61%)
Prev Close
€3.27
Open
€3.27
Day's High
€3.28
Day's Low
€3.22
Volume
195,256
Avg. Vol
121,878
52-wk High
€3.30
52-wk Low
€2.37

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.88
Market Cap(Mil.): €226.54
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure

* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

30 Nov 2017

BRIEF-Valneva 9M EBITDA increases to 12.3 million euros

* TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO‍​

09 Nov 2017

BRIEF-Valneva signs contract with US government

* ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT

08 Nov 2017

BRIEF-Valneva H1 EBITDA rises to 7.6 million euros

* ‍EBITDA INCREASED STRONGLY IN H1 2017 REACHING EUR 7.6 MILLION (VERSUS. EUR 4.7 MILLION IN H1 2016)​

31 Aug 2017

BRIEF-Valneva appoints David Lawrence as Chief Financial Officer

* LAWRENCE'S AND BENDER'S APPOINTMENTS BY THE COMPANY'S SUPERVISORY BOARD WILL BECOME EFFECTIVE ON AUGUST 7TH AND SEPTEMBER 1ST RESPECTIVELY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Aug 2017

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

27 Jul 2017

BRIEF-Valneva receives FDA fast track designation for its lyme disease vaccine candidate VLA15

* REG-VALNEVA RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LYME DISEASE VACCINE CANDIDATE VLA15

24 Jul 2017

Earnings vs. Estimates